GuidelineCanadian journal of gastroenterology = Journal canadien de gastroenterologie2009
Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.
Guideline in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Canadian Association of Gastroenterology policy on the application for, and implementation of, clinical practice guidelines.Canadian journal of gastroenterology & hepatology · 2014Guideline
- Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.Canadian journal of gastroenterology & hepatology · 2014Guideline
- Is there a standardized practice for the development of international ulcerative colitis and Crohn's disease treatment guidelines?Gastroenterology report · 2021Article
- A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease.Journal of the Canadian Association of Gastroenterology · 2021Article
- Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease.Intestinal research · 2020Article
- [Neutrophil-lymphocyte ratio at 14th week predicts loss of response to 52-week infliximab therapy in patients with Crohn's disease].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.Drugs · 2020Review
- Contemporary surgical practice in the management of anal fistula: results from an international survey.Techniques in coloproctology · 2019Article
- Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care.World journal of gastroenterology · 2013Review
- Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.World journal of gastroenterology · 2012Article
- Certolizumab pegol for the treatment of Crohn's disease.Therapeutic advances in gastroenterology · 2011Article
- Health care resource use and costs in Crohn's disease before and after infliximab therapy.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2011Article
- Navigating the complexity of ulcerative colitis: challenging case example.Canadian family physician Medecin de famille canadien · 2011Article
- Assessing patients' satisfaction with anti-TNFα treatment in Crohn's disease: qualitative steps of the development of a new questionnaire.Clinical and experimental gastroenterology · 2011Article
- Preparing the patient for immunosuppressive therapy.Current gastroenterology reports · 2010Review
- Summary of the Canadian Association of Gastroenterology 2004 strategic plan.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2010Article
- Diffusion-Weighted MR Enterography to Monitor Bowel Inflammation after Medical Therapy in Crohn's Disease: A Prospective Longitudinal Study.Korean journal of radiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuidelines regarding the use of infliximab in Crohn's disease were previously published by the Canadian Association of Gastroenterology in 2004. However, recent clinical findings and drug developments warrant a review and update of these guidelines.
objectiveTo review and update Canadian guidelines regarding the use of tumour necrosis factor-alpha antibody therapy in both luminal and fistulizing Crohn's disease.
methodsA consensus group of 25 voting participants developed a series of recommendation statements that addressed pertinent clinical questions and gaps in existing knowledge. An iterative voting and feedback process was used in advance of the consensus meeting in conjunction with a systematic literature review to refine the voting statements. These statements were brought to a formal consensus meeting held in Montreal, Quebec (March 2008), wherein each statement underwent discussion, reformulation, voting and subsequent revision until group consensus was obtained (at least 80% agreement). OUTCOME: The 47 voting statements addressed three themes: induction therapy, maintenance therapy and safety issues. As a result of the iterative process, 23 statements achieved consensus and were submitted for publication.
conclusionIn the past five years, tumour necrosis factor-alpha antagonist therapy has become a cornerstone in the management of moderate-to-severe Crohn's disease refractory to conventional treatment algorithms. The evidentiary base supporting the use of these drugs in Crohn's disease is substantial and strengthened by results from longterm clinical and molecular studies. However, significant gaps in knowledge exist, particularly with regard to treatment failure. Confidence in the safety of these drugs is increasing, provided that therapy is administered in a clinical setting in which potential complications can be readily recognized and treated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.